Meditoxin

ApprovedSmall molecule

MMedy-Tox

Meditoxin is one of 94 small molecule programs targeting Cervical Dystonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

SpasticityActive, not recruiting

HyperhidrosisActive, not recruiting

Overactive BladderActive, not recruiting

HypertrophyActive, not recruiting

Cervical DystoniaPhase 3

Active, not recruiting

SpasticityApproved

Active, not recruiting

HyperhidrosisPhase 3

Active, not recruiting

Overactive BladderPhase 1

Active, not recruiting

HypertrophyPhase 3

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Meditoxin

MMedy-Tox

Approved

1 2

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

3 3

Botox

AbbVie

Phase 3

3 4

GSK1358820

GSK

Phase 3

1 5

Tolterodine PR

Pfizer

Phase 3

5 6

Oxybutynin Chloride

Mylan Pharmaceuticals Inc

Phase 3

3 7

Vesicare

Astellas

Phase 3

2 8

YM178

Astellas

Phase 3

6 9

SPM 907

Pfizer

Phase 3

5 10

Standard Medication Therapy

QQing Yuan

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Dystonia2 trials

Meditoxin® Treatment in Patients With Cervical Dystonia

Completed·MMedy-Tox·Phase 3·NCT03232320·66 enrolled

Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy

Completed·SSeoul National University Hospital·Phase 4·NCT01860196·17 enrolled

Hypertrophy1 trial

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

Completed·MMedy-Tox·Phase 3·NCT03452345·180 enrolled

Hyperhidrosis1 trial

Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis

Completed·MMedy-Tox·Phase 3·NCT03760198·220 enrolled

Overactive Bladder1 trial

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Completed·MMedy-Tox·Phase 1·NCT03371342·30 enrolled

Spasticity1 trial

MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity

Completed·MMedy-Tox·Phase 4·NCT03908580·120 enrolled

2 more indications

Safety and Efficacy1 trial

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines

Completed·MMedy-Tox·Phase 4·NCT03289169·300 enrolled

Unspecified2 trials

Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

Completed·MMedy-Tox·Phase 1·NCT03647982·13 enrolled

Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers

Completed·MMedy-Tox·Phase 1·NCT03317717·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Meditoxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meditoxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meditoxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medy-Tox company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMedy-Tox

Meditoxin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Dystonia2 trials

Hypertrophy1 trial

Hyperhidrosis1 trial

Overactive Bladder1 trial

Spasticity1 trial

Safety and Efficacy1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News